Stifel on Neumora Therapeutics (NMRA): ' it's hard to have much conviction in the mechanism in MDD'
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Hold rating and $2.00 price target on Neumora Therapeutics (NASDAQ: NMRA).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
